Showing results (51-60 of 98) with videos related to
Sort By:
Pageof 10
Cancer Chemotherapy and Pharmacology|October 22, 2008
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patientsEmilio Bajetta, Maria Di Bartolomeo, Roberto Buzzoni, et al.Tumori|March 15, 2005
Treatment options in hormone-refractory metastatic prostate carcinomaAlberto Fusi, Giuseppe Procopio, Silvia Della Torre, et al.Cancer Chemotherapy and Pharmacology|August 29, 2006
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?Emilio Bajetta, Laura Catena, Giuseppe Procopio, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2005
Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older womenEmilio Bajetta, Giuseppe Procopio, Luigi Celio, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2008
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?Diego Cortinovis, Paolo Bidoli, Daniela Cullurà, et al.Tumori|October 28, 2009
Pitfalls in the diagnosis of neuroendocrine tumors: atypical clinical and radiological findings as cause of medical mistakesEmilio Bajetta, Laura Catena, Monika Ducceschi, et al.Future Oncology (London, England)|August 23, 2014
Safety profile and treatment response of everolimus in different solid tumors: an observational studyElena Verzoni, Sara Pusceddu, Roberto Buzzoni, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 12, 2015
Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancerMaria Di Bartolomeo, Filippo Pietrantonio, Alessandro Pellegrinelli, et al.European Journal of Cancer (Oxford, England : 1990)|February 1, 2015
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II studyMaria Di Bartolomeo, Andrea Ciarlo, Alessandro Bertolini, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trialAnthony Howell, John F R Robertson, Paul Abram, et al.Pageof 10